Shenzhen Cervical Cancer Screening Trial III
Using the residual stored DNA from the Cervista High Risk HPV assay used in SHENCCAST II, we tested the SHENCCAST II dataset (noted above) with the new Cervista 16/18 HPV assay. These data was presented at Eurogin 2011, Lisbon, Portugal and published by Wu et.al. J Low Genit Tract Dis. 2012 Oct;16(4):416-20.
It has been suggested and recommended that using a specific 16/18 assay as a secondary screen would be an excellent method of increasing the specificity of primary HR-HPV screening. This study demonstrated whichever primary test is used you significantly improve specificity by secondary screening with the Cervista 16/18 assay. The fact that world-wide 70% of the cervical cancers are either 16 or 18 positive makes this a relevant strategy to consider even with the consequential loss of sensitivity for ≥ CIN3.
We have also combined data from SHENCCAST II and III an completed “Triage of women with negative cytology and positive high-risk HPV: An analysis of data from the SHENCCAST II/III studies” (Goodrich SK, J Low Genit Tract Dis. 2013 Nov 21 (epub ahead of print PMID: 24270196).